GeneSystem Co Ltd
KOSDAQ:363250
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 520
11 030
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
G
|
GeneSystem Co Ltd
KOSDAQ:363250
|
34.3B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
391.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
GeneSystem Co Ltd
Glance View
Genesystem Co., Ltd engages in providing PCR based molecular diagnostic products. The firm is engaged in the development, manufacture and sale of platform based on molecular diagnosis. The firm develops and manufactures products such as molecular diagnosis systems, biochips, test kits, and reaction reagents, among others. The firm develops in vitro diagnostic technology through immunodiagnosis technology and molecular diagnosis technology.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for GeneSystem Co Ltd is -2 589.3%, which is below its 3-year median of -945.5%.
Over the last 3 years, GeneSystem Co Ltd’s Net Margin has decreased from -38.6% to -2 589.3%. During this period, it reached a low of -2 589.3% on Sep 30, 2025 and a high of -38.6% on Sep 30, 2022.